Search
Medifoxamine
go.drugbank.com/drugs/DB13219ApprovedMedifoxamine was marketed as an atypical antidepressant, with anxiolyitc properties in France, Spain, and Morrocco in the 1990s but was later withdrawn from the market due to it causing cases of hepatotoxicity
Oleic Acid
go.drugbank.com/drugs/DB04224ApprovedInvestigationalVet approvedIt is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed)
Linaclotide
go.drugbank.com/drugs/DB08890ApprovedInvestigationalLinaclotide is a synthetic 14-amino acid cyclic peptide and first-in-class guanylate cyclase-C (G-CC) agonist. Linaclotide is structurally related to human guanylin and uroguanylin, paracrine peptide hormones that are endogenous activato...
Hydroxychloroquine
go.drugbank.com/drugs/DB01611ApprovedInvestigational[L8072] It was developed during World War II as a derivative of [quinacrine] with less severe side effects.
Epirubicin
go.drugbank.com/drugs/DB00445ApprovedInvestigationalAn anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
T487
go.drugbank.com/drugs/DB05474ExperimentalThe formulation is administered orally and has anti-inflammatory effects in conditions such as rheumatoid arthritis, inflammatory bowel disease and psoriasis.
rhThrombin
go.drugbank.com/drugs/DB04923ApprovedWithdrawnCurrently, only thrombin derived from bovine blood is available in the U.S. as a stand-alone thrombin product. … rhThrombin (recombinant human thrombin) is being developed by ZymoGenetics, Inc. as a general aid to achieving hemostasis during surgery.
Zidebactam
go.drugbank.com/drugs/DB13090ApprovedZidebactam is a diazabicyclooctane that acts both as a beta-lactamase inhibitor and as an antibacterial in its own right, selectively binding penicillin-binding protein 2. … bacterial killing that persists even against organisms whose beta-lactamases zidebactam does not inhibit, including metallo-beta-lactamase producers, and against non-enzymatic resistance mechanisms such as
Clobutinol
go.drugbank.com/drugs/DB09004ApprovedWithdrawnClobutinol is a cough suppressant that is withdrawn from the US and EU markets. Clobutinol may prolong the QT interval. In 2007, Clobutinol was determined to cause cardiac arrhythmia in some patients.
Olaratumab
go.drugbank.com/drugs/DB06043ApprovedInvestigationalOlaratumab was granted accelerated approval (as Lartruvo) as initial therapy to treat adults with certain types of soft tissue sarcoma (STS) in October, 2016.